GLP-1 Monitoring Schedule Template for Med Spas (2026)
The complete, ready-to-adapt monitoring schedule for a med spa GLP-1 program — baseline labs, titration follow-ups, dose-escalation checkpoints, a side-effect triage table, and exactly what to document at every visit.
In short
This is a working GLP-1 monitoring schedule template, not a theory piece. Below you will find the baseline workup before the first injection, the week-by-week titration cadence, the checkpoints for advancing or holding a dose, a side-effect triage table, and a per-visit documentation checklist. Treat it as a documentation and operations framework that your supervising provider reviews and adapts — it is what boards and malpractice carriers look for when they ask whether your weight-loss program is actually being monitored.
If your med spa runs a semaglutide or tirzepatide program, the most valuable document you can own is not the injection protocol — it is the monitoring schedule. It is the piece that proves you did not simply hand a patient a pen and a titration card. It shows that you screened them, saw them on a defined cadence, made deliberate decisions about when to advance the dose, watched for the complications that matter, and wrote all of it down.
This article gives you that schedule as a usable template. Every table below is designed to be lifted into your own charting system or standard operating procedure and adapted by your supervising provider. Nothing here is clinical advice for treating an individual patient — the dosing figures track the FDA labels, and the monitoring cadence reflects common weight-management practice, but the licensed prescriber who performs the good faith exam is always the one who decides what is right for the person in front of them.
For the full regulatory picture around who may prescribe and how programs are structured, keep our GLP-1 med spa compliance guide open in another tab. This post is the operational companion to it: the calendar and the paperwork.
- Before dose 1: Full history, contraindication screen, vitals, and baseline labs (CMP, HbA1c, lipids, TSH, ± lipase, pregnancy test where relevant)
- Weeks 1–4: First check-in at week 4 before any escalation — tolerance, hydration, side-effect review
- Months 2–6: A visit before every dose increase (~every 4 weeks), then quarterly on maintenance
- Always: Same-day contact for red-flag symptoms; document the escalation decision and rationale every visit
- Signed by: The supervising provider, tied back to a documented good faith exam
Why Every Med Spa GLP-1 Program Needs a Written Monitoring Schedule
Weight-loss medicine is one of the fastest-growing services in aesthetics — and one of the most heavily scrutinized. GLP-1 receptor agonists are prescription drugs with a boxed warning, real contraindications, and a titration ladder that exists specifically to reduce harm. When a med spa dispenses them without a documented monitoring plan, every one of those risks becomes a liability exposure.
The compliance angle: a schedule is evidence
State medical boards and malpractice carriers do not primarily ask whether your outcomes were good. They ask whether you met the standard of care and can prove it. A written monitoring schedule — followed and documented — is the single cleanest way to show that your program screens patients, escalates deliberately, and reacts to complications. Without it, an adverse event becomes your word against the chart, and an empty chart never wins.
The clinical angle: titration is where things go wrong
Most GLP-1 problems are dose-related and time-related. Nausea, vomiting, dehydration, and gallbladder issues cluster around escalations and rapid weight loss. A schedule that forces a check-in before each dose increase catches the patient who should not advance yet — which is exactly the patient who ends up in an emergency room when no one is watching.
The business angle: retention lives in the follow-up
There is a commercial reason too. Patients who are monitored, coached, and reassured stay in the program. The visit cadence below is also your revenue cadence. A structured schedule turns a one-time script into a managed, months-long relationship — which is the entire economic case for offering the service in the first place.
It is worth being explicit about what this template is and is not. It is a documentation and operations framework: a defined set of tables that tells your team what to collect, when to collect it, and what to do with the answers. It is not a substitute for clinical judgment, and it does not replace the good faith exam, the prescriber's diagnosis, or the individualized plan that a licensed provider builds for each patient. Think of it as the rails the program runs on — the provider still drives the train, but the rails keep every patient on the same safe, documented track from the first injection through maintenance or off-ramp.
The Baseline Workup: Before the First Injection
The baseline visit is the foundation of the whole schedule. It establishes eligibility, screens for the labeled contraindications, and captures the starting numbers you will measure everything else against. Nothing is injected until this is complete and the prescriber has performed a good faith exam and issued an order.
| Category | What to Collect | Why It Matters |
|---|---|---|
| History & contraindication screen | Personal/family history of medullary thyroid carcinoma or MEN 2; history of pancreatitis; gallbladder disease; severe GI disease; current medications (including insulin/sulfonylureas) | MTC/MEN 2 are labeled contraindications; the rest drive risk and dose decisions |
| Vitals & anthropometrics | Weight, height, BMI, waist circumference, blood pressure, heart rate | Establishes the baseline the program is measured against |
| Core labs | CMP (renal/hepatic/electrolytes), HbA1c, fasting lipid panel | Screens for diabetes and organ function; sets metabolic baseline |
| Add-on labs (risk-based) | TSH; baseline lipase where pancreatitis risk is present; CBC as indicated | Thyroid and pancreatic baselines aid later interpretation |
| Pregnancy & reproductive | Pregnancy test for anyone who could become pregnant; contraception counseling | GLP-1 agonists are not used in pregnancy |
| Counseling & consent | Informed consent, nutrition and protein counseling, injection-technique teaching, expectation setting | Documents education and the good faith exam |
The lab panel is deliberately conservative. Some programs add fasting glucose, vitamin D, or a metabolic ratio panel; others keep it lean. The point of the template is that the panel is defined in advance and applied consistently — the prescriber then adds or removes based on the individual. For the administration and screening steps that pair with this workup, see our GLP-1 injection protocol for med spas, which covers technique and the pre-injection checklist in detail.
Weeks 1–4: The Titration Monitoring Schedule
The first month is the highest-attention window. This is when the patient learns to inject, when the earliest GI side effects appear, and when you decide whether they are ready to move up. The labels for both semaglutide (Wegovy) and tirzepatide (Zepbound) hold each starting dose for four weeks before the first increase, so the week-4 visit is the natural first checkpoint.
| Timepoint | Contact Type | What to Assess & Record |
|---|---|---|
| Day 0 (first dose) | In-clinic | Confirm baseline complete; administer or teach starting dose; hydration and nausea counseling; red-flag education |
| Day 3–7 | Message or call (optional) | Early tolerance check; injection-site questions; confirm no severe GI symptoms |
| Week 4 | Visit (escalation checkpoint) | Weight, vitals, structured side-effect review, hydration, adherence; decision to advance, hold, or reduce |
The first-dose visit
Day 0 is teaching-heavy. The patient leaves knowing how to inject, what a normal side effect feels like, what a red flag feels like, and how to reach you same-day. Document the counseling — it is part of your good faith exam trail.
The optional early touchpoint
A short message or call in the first week is not clinically mandatory, but it catches the anxious patient before they quit and the intolerant patient before they get dehydrated. It is cheap insurance and strong retention.
The week-4 escalation checkpoint
This is the first true decision point. The patient does not advance automatically — they advance only if they tolerated the starting dose. The criteria for that decision are in the escalation section below.
Months 2–6: Ongoing Follow-Up Cadence
After the first month, the schedule settles into a rhythm tied to the titration ladder: a visit before each planned dose increase, roughly every four weeks, until the patient reaches a dose that controls appetite and is well tolerated. Once they are stable on a maintenance dose, the cadence stretches to quarterly.
| Phase | Visit Frequency | Focus |
|---|---|---|
| Active titration (mo. 2–4) | Every ~4 weeks, before each dose step | Tolerance, weight trend, escalation decision, side-effect triage |
| Reaching target (mo. 4–6) | Every 4–8 weeks | Rate of loss, muscle-mass check-in, plateau planning |
| Maintenance | At least every 3 months | Weight stability, labs as indicated, off-ramp or continuation decision |
| Repeat labs | Provider-directed (e.g., ~3 months, then periodically) | Recheck metabolic panel/HbA1c/lipids per clinical judgment |
Repeat labs are intentionally left to provider judgment rather than a rigid calendar, because the right interval depends on the patient's comorbidities and how the numbers looked at baseline. What the template fixes is that a decision about repeat labs is made and recorded at the maintenance transition, rather than forgotten. For patients approaching their goal, our GLP-1 maintenance and off-ramping guide covers the taper decisions in depth.
Dose-Escalation Checkpoints: When to Advance, Hold, or Step Back
The heart of the schedule is the escalation decision. Both agents follow a fixed label ladder, but the ladder is a ceiling, not a mandate — you move up only when the patient is ready. Here are the label-consistent titration steps for reference.
| Interval | Semaglutide (Wegovy) | Tirzepatide (Zepbound) |
|---|---|---|
| Weeks 1–4 | 0.25 mg weekly | 2.5 mg weekly |
| Weeks 5–8 | 0.5 mg weekly | 5 mg weekly |
| Weeks 9–12 | 1.0 mg weekly | 7.5 mg weekly |
| Weeks 13–16 | 1.7 mg weekly | 10 mg weekly |
| Weeks 17+ | 2.4 mg weekly (maintenance) | 12.5 mg → 15 mg (maintenance 5 / 10 / 15 mg) |
Criteria to advance
Advance to the next step only when the patient has completed at least four weeks at the current dose, tolerated it (no more than mild, manageable side effects), remained hydrated with adequate oral intake, and still has appetite or weight-loss headroom to justify more medication.
Criteria to hold
Stay at the current dose when the patient is still having moderate GI symptoms, has not completed the interval, is losing weight well and does not need more drug, or has any red flag under evaluation. Holding is a legitimate, common decision — the label ladders exist precisely to allow it.
Criteria to step back
Reduce to the prior dose when side effects are intolerable at the current dose, when there are signs of dehydration or rapid lean-mass loss, or when the patient simply cannot function. A step back is a clinical decision, not a failure, and it should be documented with its rationale like any other.
The Side-Effect Triage Table: What Triggers a Same-Day Call
A monitoring schedule is only as good as its escalation logic. Patients need to know — and your chart needs to show they were told — which symptoms are expected and self-limiting versus which mean stop and call now. The American Med Spa Association and standard weight-management practice both stress that the supervising prescriber must be reachable for exactly these situations.
| Symptom / Finding | Severity | Action |
|---|---|---|
| Mild nausea, early satiety, mild reflux | Expected | Diet and hydration counseling; continue; reassess at next visit |
| Persistent vomiting / diarrhea, poor intake | Escalate | Same-day provider contact; hold escalation; assess dehydration; consider dose reduction |
| Severe abdominal pain radiating to the back | Red flag | Stop drug; urgent evaluation for pancreatitis; refer to emergency care |
| RUQ pain, fever, jaundice | Red flag | Stop drug; evaluate for gallbladder disease; refer |
| Neck mass, hoarseness, trouble swallowing | Red flag | Stop drug; evaluate per thyroid tumor boxed warning; refer |
| Shakiness/confusion (on insulin or sulfonylurea) | Escalate | Assess hypoglycemia; coordinate with prescriber to adjust the other agent |
The hypoglycemia row matters specifically for patients who arrive already on insulin or a sulfonylurea — GLP-1 therapy can unmask lows that were previously masked by overeating, and the fix is coordinating the other medication, not the GLP-1. This is one more reason the monitoring schedule captures a full medication list at baseline.
Get the complete GLP-1 protocol library.
The Weight Loss Kit includes the monitoring schedule SOP plus 9 more protocols: screening, dosing, side-effect management, documentation templates, and emergency escalation — ready to adapt to your practice.
View Weight Loss Kit — $297Monitoring Body Composition and Muscle Loss
One of the most important — and most under-monitored — aspects of GLP-1 therapy is what the weight loss is made of. Rapid weight loss on any modality carries a risk of losing lean muscle mass alongside fat, and GLP-1 programs are no exception. A monitoring schedule that only tracks the scale number misses this entirely.
What to track
At minimum, record the rate of weight loss and watch for losses that are faster than roughly 1–2% of body weight per week over sustained periods. Where available, add a body-composition measure — bioimpedance analysis, a simple strength or grip check, or waist-to-height ratio — to distinguish fat loss from lean-mass loss. The template calls for a muscle-mass check-in during the months 4–6 phase, when cumulative loss is greatest.
What to intervene on
The intervention is rarely the drug — it is protein intake and resistance training. Counseling on adequate dietary protein and regular strength work is part of the visit, and it is documented like any other clinical instruction. When lean-mass loss looks excessive, slowing titration or holding the dose is a legitimate response. Our dedicated GLP-1 muscle loss and body composition guide goes deep on the measurement tools and the protein and training targets.
Why does this belong in the monitoring schedule at all? Because body-composition quality is increasingly how patients and referring physicians judge a weight-loss program, and because a chart that shows you tracked muscle mass — not just the scale — is powerful evidence that your program practiced modern, thoughtful medicine rather than simply dispensing a drug. Building a single recurring line into your maintenance-phase note, even a qualitative one, keeps the topic from disappearing once the early GI side effects settle down and the visits get shorter. It also gives you a natural, non-salesy reason to keep the patient engaged: measuring progress is a service, and it is one patients happily return for.
Get the Free Med Spa Compliance Checklist
The fast self-audit for weight-loss and injectable programs — see exactly where your documentation, monitoring, and oversight gaps are before a board or a carrier does.
It usually lands in your Promotions tab (or spam) — move it to your inbox and add MedSpa Standards to your contacts so you don't miss the follow-ups.
Transitioning to Maintenance or Off-Ramping
Every GLP-1 patient eventually reaches a fork: continue on a maintenance dose, or begin tapering off. The monitoring schedule does not end here — it changes shape. The decision itself is a documented event, and the follow-up continues at a quarterly minimum through the transition.
The maintenance transition
When a patient reaches their goal or a well-tolerated plateau, the visit converts from titration decisions to stability monitoring: is the weight holding, are the labs where they should be, is muscle mass preserved, and is continued therapy still indicated? Record the maintenance dose, the rationale, and the plan for the next review.
The off-ramp decision
If the plan is to taper, the schedule tracks the step-down and, critically, watches for weight regain — which is common and expected without a maintenance strategy. Counseling on nutrition, activity, and the possibility of resuming therapy belongs in the note. Oral GLP-1 options are increasingly part of this conversation; see our oral GLP-1 guide for med spas and, for tirzepatide-specific dosing considerations, the tirzepatide protocol.
What to Document at Every Visit (the Part Regulators Check)
This is the compliance core of the template. A monitoring schedule that is followed but not documented is, for legal purposes, a schedule that never happened. Every visit note should be able to answer, on its own, what you checked, what you decided, and why. The American Diabetes Association's Standards of Care reinforce structured follow-up and documentation for anti-obesity pharmacotherapy.
| Field | Example Entry |
|---|---|
| Weight, BMI, vitals | Objective numbers with change since last visit |
| Current dose & start date | Drug, dose, date started at this step |
| Side-effect review | Structured GI/red-flag review, positive and negative findings |
| Adherence & technique | Missed doses, injection-site rotation, storage |
| Escalation decision + rationale | Advance / hold / reduce, and the reason |
| Counseling provided | Nutrition, hydration, protein, resistance training |
| Next steps & provider sign-off | Next visit date; GFE reference; supervising provider review |
If you build only one thing from this article, build this table into your chart template. It is the difference between a program that looks defensible and one that is. When a plaintiff attorney or a board investigator asks how the patient was monitored, the answer is a stack of complete, signed notes — not a memory.
A practical tip: make the escalation-decision field mandatory in your charting system so a visit cannot be closed without recording advance, hold, or reduce and a one-line reason. That single required field does more to protect a weight-loss program than any other piece of documentation, because it forces the deliberate decision to exist on paper every time. The same goes for the side-effect review — a structured checklist beats a free-text box, because a checklist proves you asked about pancreatitis and gallbladder symptoms even when the answer was no. Empty free-text fields are read, in hindsight, as questions never asked.
Turning This Template Into Your Clinic's SOP
A template on a webpage is a starting point. To become a real safeguard, it has to become a signed, versioned standard operating procedure that your staff actually follows and your medical director actually endorses.
From template to signed SOP
The path is short: adapt the tables above to your service menu and state, have your supervising provider review and modify anything that does not fit your patient population, add a version number and review date, obtain the provider's signature, and train every staff member who touches the program. Then schedule an annual review so the SOP does not drift out of date as labels and state rules change.
Who does what
Assign each role explicitly. As AmSpa notes, the prescriber must perform the good faith exam and cannot delegate it; a registered nurse can administer and gather monitoring data under a valid order, but only after that exam. Naming the responsible person for each step is part of what makes the schedule defensible. For the full role-by-role and state-by-state picture, our weight-loss injections compliance guide is the reference.
Don't rebuild it from scratch
You do not need to author these documents from a blank page. A professionally written, physician-ready set of weight-loss SOPs — monitoring schedule included — gives your medical director a sound foundation to review and sign in days rather than weeks. That is the entire premise of our complete med spa compliance SOP library: the clinical and documentation scaffolding is already built, and your provider simply adapts and signs it.